ANALYSIS OF DRUG SUPPLY EXPENDITURES ON PATIENTS ON D MONITORING WITH GLOMERULAR DISEASE IN SHYMKENT

Glomerular diseases are a significant public health issue, often leading to chronic kidney disease (CKD) and increased healthcare costs. Patients registered for D monitoring require continuous medication management, making drug supply expenditures a critical aspect of treatment sustainability. Understanding the trends in drug expenditures can help optimize resource allocation and improve patient outcomes. Methods: A retrospective analysis was conducted using data from the Information System for Outpatient Drug Supply Management (ISLO) for patients with glomerular disease in Shymkent, Kazakhstan, from 2019 to 2023. The study examined the number of prescriptions issued and the corresponding financial expenditures. Statistical trends were assessed to identify changes over the study period. Results: The study revealed a significant increase in prescriptions from 2019 to 2020, followed by a consistent decline in subsequent years. A similar trend was observed in financial expenditures, peaking in 2020 and decreasing thereafter. These fluctuations suggest possible adjustments in healthcare policy, changes in patient registration, or variations in treatment protocols. Discussion: The findings indicate a potential reduction in healthcare resources allocated to glomerular disease management, despite the increasing prevalence of CKD. The decline in expenditures could be attributed to cost-cutting measures, shifts in prescription patterns, or limitations in drug supply. Ensuring sustainable healthcare financing is crucial to maintaining effective treatment and preventing long-term complications. Conclusion: This study highlights the need for strategic resource allocation and consistent funding for outpatient drug supply programs. Sustainable healthcare policies are essential to ensuring continued access to medications and improving the management of glomerular diseases.